ZA9010319B - Use of an anticoagulant as a diagnostic agent - Google Patents

Use of an anticoagulant as a diagnostic agent

Info

Publication number
ZA9010319B
ZA9010319B ZA9010319A ZA9010319A ZA9010319B ZA 9010319 B ZA9010319 B ZA 9010319B ZA 9010319 A ZA9010319 A ZA 9010319A ZA 9010319 A ZA9010319 A ZA 9010319A ZA 9010319 B ZA9010319 B ZA 9010319B
Authority
ZA
South Africa
Prior art keywords
anticoagulant
esp
new
diagnostic agent
compsns
Prior art date
Application number
ZA9010319A
Inventor
Christiaan Pe Reutelingsperger
Peter Maria Reuteli Christiaan
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6396455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9010319(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ZA9010319B publication Critical patent/ZA9010319B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/087—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4718—Lipocortins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Dental Preparations (AREA)

Abstract

Anticoagulant polypeptides (I) of the annexin family, labelled with a detectable marker are new. Also new are compsns. contg. (I) plus auxiliaries. (I) is esp. VAC (vascular anticoagulant protein) and suitable markers include fluorescein isothiocyanate, a radioisotope (esp. 131- or 125-iodine) or a paramagnetic contrast agent. (I), which can be administered intravenously or intraarterially, are formulated with physiological saline, 'Tween 80', arginine and/or phosphate buffer. The compsn. may also include an anticoagulant, esp. heparin, which has no effect on plasma Ca concn.
ZA9010319A 1989-12-27 1990-12-21 Use of an anticoagulant as a diagnostic agent ZA9010319B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3942988 1989-12-27

Publications (1)

Publication Number Publication Date
ZA9010319B true ZA9010319B (en) 1992-08-26

Family

ID=6396455

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9010319A ZA9010319B (en) 1989-12-27 1990-12-21 Use of an anticoagulant as a diagnostic agent

Country Status (15)

Country Link
EP (2) EP0509026B1 (en)
JP (1) JP3135261B2 (en)
KR (1) KR0181520B1 (en)
AT (2) ATE429644T1 (en)
AU (1) AU642202B2 (en)
CA (1) CA2070647C (en)
DE (3) DE59010815D1 (en)
ES (1) ES2113372T3 (en)
FI (1) FI107586B (en)
HU (2) HU209650B (en)
NO (1) NO305276B1 (en)
NZ (1) NZ236620A (en)
PT (1) PT96385B (en)
WO (1) WO1991009628A1 (en)
ZA (1) ZA9010319B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025240A2 (en) * 1992-06-09 1993-12-23 Neorx Corporation Pretargeting methods and compounds
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
AU1186295A (en) * 1993-11-24 1995-06-13 University Of Washington Blood coagulation retardants and devices
DE69530375T2 (en) * 1994-01-24 2004-02-05 Neorx Corp., Seattle RADIOACTIVE-MARKED ANNEXINE
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
HUT76623A (en) * 1994-03-16 1997-10-28 Mallinckrodt Medical Inc Stabilization of peptides and proteins for radiopharmaceutical use
AU689248B2 (en) * 1994-04-11 1998-03-26 Nexins Research B.V. A method for detecting and/or optionally quantifying and/or separating apoptotic cells in or from a sample
JPH10504534A (en) * 1994-06-16 1998-05-06 ネオルクス コーポレイション Radiolabeled annexin-galactose conjugate
EP1364964A1 (en) * 1994-06-16 2003-11-26 Neorx Corporation Radiolabeled annexingalactose conjugates
EP1486509A3 (en) * 1994-12-07 2005-03-23 Neorx Corporation Radiolabeled annexin-galactose cluster conjugates
EP0799050B1 (en) * 1994-12-07 2004-08-11 Neorx Corporation Radiolabeled annexin-galactose cluster conjugates
US5886143A (en) * 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
US5955605A (en) * 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
FR2736197B1 (en) * 1995-06-29 1997-09-12 Univ Paris Curie MAGNETIC NANOPARTICLES COUPLED WITH ANNEXIN AND THEIR USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) * 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US4455290A (en) * 1981-04-02 1984-06-19 Research Corporation Inhibition of fibrin polymerization by a peptide isolated from fibrin Fragment D1
US4820505A (en) * 1985-04-04 1989-04-11 Scripps Clinic And Research Foundation Detection of activated platelets with antibodies to thrombospondin
PT87083B (en) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int A PROCESS FOR THE PREPARATION OF A VASCULAR ANTICOAGULANT PROTEIN, OF DNA THAT CODIFIES FOR THIS PROTEIN AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING IT
DE3810331A1 (en) * 1988-03-26 1989-10-05 Boehringer Ingelheim Int Monoclonal VAC antibodies

Also Published As

Publication number Publication date
PT96385B (en) 1998-06-30
HU209650B (en) 1994-09-28
HUT61491A (en) 1993-01-28
ATE164083T1 (en) 1998-04-15
DE59010815D1 (en) 1998-04-23
DE4040817A1 (en) 1991-07-04
JP3135261B2 (en) 2001-02-13
JPH05502877A (en) 1993-05-20
NO305276B1 (en) 1999-05-03
DE59010946D1 (en) 2009-06-04
WO1991009628A1 (en) 1991-07-11
KR920703121A (en) 1992-12-17
CA2070647C (en) 2001-04-10
AU7071191A (en) 1991-07-24
AU642202B2 (en) 1993-10-14
NO922528L (en) 1992-08-26
KR0181520B1 (en) 1999-05-01
EP0806670A2 (en) 1997-11-12
PT96385A (en) 1991-10-31
EP0806670B1 (en) 2009-04-22
CA2070647A1 (en) 1991-06-28
EP0806670A3 (en) 1997-12-10
FI922719A0 (en) 1992-06-12
NZ236620A (en) 1997-03-24
ATE429644T1 (en) 2009-05-15
EP0509026A1 (en) 1992-10-21
HU9202149D0 (en) 1992-10-28
EP0509026B1 (en) 1998-03-18
ES2113372T3 (en) 1998-05-01
FI107586B (en) 2001-09-14
NO922528D0 (en) 1992-06-26

Similar Documents

Publication Publication Date Title
AU642202B2 (en) Use of an anticoagulant as a diagnostic agent
SE8000469L (en) TISSUE BINDING AND PROCEDURE FOR ITS MANUFACTURING AND USING THE BINDING AGENT
NO2002002I2 (en) Ferukarbotran
ATE123301T1 (en) GENETICALLY PRODUCED APROTININE HOMOLOGUE.
PROPP et al. Hemangioma-thrombocytopenia syndrome associated with microangiopathic hemolytic anemia
ES2151517T3 (en) EFFECTS OF ACTINA FILAMENTS ON THE STRUCTURE AND LISIS OF FIBRINE COAGULES.
HU902004D0 (en) New trombolitic preparations
DE69001686D1 (en) TREATING LEUCOCYTIC DISORDERS WITH GM-CSF.
ES2078289T3 (en) AGENT TO IMPROVE THE ANEXINES RECOVERY.
DK226889A (en) ALCOHOLPEPTIDE DERIVATIVES AND ITS USE TO REDUCE BLOOD COAGULATION
BG97199A (en) ANTICOAGULANT PREPARATION
Klem et al. Detection of deep venous thrombosis by DMP 444, a platelet IIb/IIIa antagonist: a preliminary report
Magee et al. The liver as a site for interferon production in response to poly I: poly C
Al-Mondhiry et al. Platelet and fibrinogen survival in calves implanted with artificial heart and ventricular assist device-correlation with autopsy findings
FI885025A (en) KOAGULATIONSHAEMMANDE PROTEIN PP4-X, DESS FRAMSTAELLNING OCH ANVAENDNING.
Ramrakhyani et al. Hepatitis B viral markers and liver disease in haemophiliacs: A study in an Indian population
Eckhardt 20. NOSSEL. HC. YOUNGER. L R.. WILNER. GD, PROCUPEZ. T.. CANFIELD. R. E., BUTLER. VP: Radioimmunassay of human fibrinopeptide A. Proc. Natl. Acad. Sei. USA 68. 2350 (1971). 21. NOSSEL HL YUDELMANN. J., CANFIELD. RE, BUTLER. VP. SPANON-DIS. K., WILNER. GD, QURESHI, GD: Measurement of fibrinopeptide A in human
Shin et al. Effect of Cycloheximide on the Specific Activity of Na+-K+-activated Adenosine Triphosphatase in Human Neonatal Erythrocytes
McCance-Katz New onset Raynaud's phenomenon in a schizophrenic patient.
Hurlbut Deep venous thrombosis of the leg: US findings: Appleman PT, De Jong TE, Lampmann LE Radiology 163: 743–746 Jun 1987
TAKETOMI et al. The ultrastructural localization of platelet factor 4 and fibronectin in human platelets
Hee Basic Principles of Nursing Care
DE69131248D1 (en) INHIBITION OF SEPARATION OF SODIUM BY NA-K-ATPASE
Yacoub et al. Intra-arterial Perfusion of Pancreatic Juice in the Hind Limb of Dogs: Effects on the Peripheral Vascular Resistance
ES2046244T3 (en) USE OF A VEHICLE WITH HIGH AFFINITY TO TUMORS.